02552 華領醫藥－Ｂ
按盘价 
2.090 +0.030 (+1.456%) 盈利能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 资产回报率 (%) | -15.381% | -14.840% | -20.099% | -30.992% | -32.052% |
| 股东资金回报率 (%) | N/A | -110.962% | -55.762% | -55.077% | -43.849% |
| 资本运用回报率 (%) | -20.897% | -14.337% | -21.810% | -40.887% | -36.002% |
边际利润分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 毛利率 (%) | 48.741% | 48.785% | 43.690% | N/A | N/A |
| 未计利息、税项、折旧及摊销前利润率 (%) | -86.126% | -239.657% | -979.050% | N/A | N/A |
| 税前边际利润率 (%) | -97.754% | -275.726% | -1156.355% | N/A | N/A |
| 纯利率 (%) | -97.754% | -275.726% | -1156.355% | N/A | N/A |
变现能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 流动比率 (X) | 4.047 X | 6.239 X | 4.991 X | 6.592 X | 9.810 X |
| 速动比率 (X) | 3.663 X | 6.062 X | 4.981 X | 6.592 X | 9.810 X |
财务杠杆分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 总负债 / 总资产比率 (%) | 108.870% | 94.137% | 75.071% | 50.160% | 38.883% |
| 总债项 / 总资产比率 (%) | 19.654% | 9.723% | 8.701% | 7.916% | 6.735% |
| 净债项 / 总资产比率 (%) | -54.971% | -74.944% | -35.047% | -66.815% | -79.379% |
| 总债项 / 股东资金比率 (%) | N/A | 165.845% | 34.903% | 15.883% | 11.019% |
| 长期债项 / 股东资金比率 (%) | N/A | 124.846% | 15.083% | 12.931% | 9.449% |
| 净债项 / 股东资金比率 (%) | N/A | -1278.356% | -140.586% | -134.059% | -129.881% |
| 净现金 / (债项) ($) | 8.40亿 | 12.93亿 | 3.93亿 | 6.04亿 | 9.51亿 |
| 每股净现金 / (债项) ($) | 0.795 | 1.225 | 0.372 | 0.572 | 0.902 |
| 总债项 / 资本运用比率 (%) | 25.077% | 11.386% | 10.458% | 8.978% | 7.392% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 存货周转率日数 (日) | 238.347日 | 216.520日 | 70.532日 | N/A | N/A |
| 应收贸易帐周转率日数 (日) | 24.980日 | 28.010日 | 230.647日 | N/A | N/A |
| 应付贸易帐周转率日数 (日) | 82.270日 | 172.983日 | 464.230日 | N/A | N/A |
| 备注： | 实时报价更新时间为16/05/2025 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | RMB -250,144,000 |
| 增长率 | 18.420% |
| 每股盈利/(亏损) | RMB -0.250 |
| 每股账面资产净值 (¥) | RMB -0.128 |